Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib in Combination With Endocrine Therapy in HR+, HER2-, PIK3CA Mutant Metastatic Breast Cancer
NCT04762979Phase 2Active, not recruiting
- Sponsor
- Marina N. Sharifi
- Start
- Feb 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Marina N. Sharifi. Started Feb 2021; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04762979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762979.